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Allogeneic stem cell transplantation is a curative treatment option for many hematological diseases, and the
numbers of transplantations are steadily increasing worldwide. Major progress has been made in lowering
treatment-related mortality by reducing intensity of the conditioning regimen and by improving supportive
care (eg, for infectious complications). Accordingly, relapse after allogeneic stem cell transplantation has
become the major cause for treatment failure. Major efforts to prevent or treat relapse are focused on cellular-
(T cell, natural killer cell), cytokine-, or antibody-based strategies to enhance the graft-versus-tumor effect or
circumvent immunoescape. In the more recent years, new classes of agents have shown activity in several
hematological malignancies, and besides their immediate antitumor activity, most of them also possess
immune-modulatory qualities that may be useful alone or in combination with adoptive immunotherapy
after allogeneic stem cell transplantation to enhance graft-versus-tumor effects. Here, we summarize the
current knowledge and potential use of 2 of these compounds in preventing or treating relapse after allo-
geneic stem cell transplantation, namely immune-modulating drugs and hypomethylating agents.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is an
effective and curative treatment approach for hematological
malignancies. The curative potential is mainly attributed to
a strong graft-versus-leukemia (GvL) reaction mediated by
allogeneic T lymphocytes and natural killer (NK) cells, which
target leukemic recipient cells by distinct mechanisms.
Donor lymphocyte infusion (DLI) after transplantation may
augment the GvL effect and is, therefore, widely used to
prevent or treat relapse after allo-SCT. However, DLI is
associated with an increased risk of acute and chronic graft-
versus-host disease (GvHD), and the majority of studies have
shown a strong correlation between response to DLI and
occurrence of GvHD. Furthermore, the effectiveness of DLI
depends on the underlying disease, and responses differ
substantially between relapsed chronic myeloid leukemia
(>80%), multiple myeloma (30% to 40%), non-Hodgkin’s
lymphoma (40% to 50%), acute myelogenous leukemia/
myelodysplastic syndrome (AML/MDS) (15% to 30%), and
acute lymphoblastic leukemia (10% to 20%) [1]. To reduce
the risk of GvHD, CD8-depleted, CD4-enriched, or suicide
geneemanipulated T cells have been investigated by several
groups [2-6]. Generation of T cells speciﬁc for minor-
histocompatibility antigens or tumor-speciﬁc antigens is
under clinical evaluation [7-9]. To increase the efﬁcacy of DLI,
immunosuppression before DLI or combination with cyto-
kine treatment (eg, interferon-a/GM-CSF or interleukin-2)edgments on page 171.
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13.09.009can also be used [10-12]. New efforts are currently under-
taken to boost GvL effect either by adoptive transfer of
leukemia-speciﬁc T cells [13], or by post-transplantation
vaccines [14]. Donor-derived NK cells exert GvL effect
without causing GvHD [15], because NK cells are thought to
speciﬁcally target host-antigenepresenting cells of hemato-
poietic origin, and, therefore, prevent the presentation of
alloantigens to donor T cells. The antileukemic effect of NK
cells may be best explained by predominant interaction of
activating receptors such as killer immunoglobulin-like
receptors (KIR) with the leukemic target cell [16-18]. Over-
all, despite the efﬁcacy of cellular therapy, there is still need
to improve results of adoptive cell therapy treatment after
allo-SCT for reducing related complications such as GvHD as
well as improving remission rate, duration, and risk of
relapse.
In addition to the development of more speciﬁc and
effective cell therapies, novel immune-modulatory drugs
may be used as post-transplantation therapies alone or
in combination with adoptive immunotherapy to augment
GvL effects of allo-SCT and/or DLI. Ideally, a drug used as
a single agent or in combination with adoptive immuno-
therapy should (1) exert additive antitumor effects either
by increasing immunologically mediated graft-versus-tumor
reactions and/or immediate anti-tumormechanism; (2) have
the capacity to reduce the risk of GvHD while maintaining
the GvL effect; (3) show a favorable toxicity proﬁle for early
application after allo-SCT; and (4) be able to inhibit immu-
nosuppressive and tolerance mechanisms in the host.
Here, we focus on the immune-modulatory properties
of immune-modulating drugs (IMIDs) and hypomethylating
agents that may be used after hematopoietic stem cell
transplantation, either alone or in combination with adop-
tive immunotherapy, to augment GvL effects.Transplantation.
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Immune-modulating drugs are thalidomide and its
analogues, lenalidomide and pomalidomide. These drugs
have an immediate antiproliferative effect on multiple
myeloma, non-Hodgkin’s lymphoma, and other hemato-
logical malignancies. In addition, antiangiogenic, anti-
inﬂammatory, and immune-modulatory properties may
contribute to antitumor effects; however, in vivo mecha-
nisms mediating tumor responses remain to be elucidated.
Thalidomide, a synthetic derivative of glutamic acid, which
caused birth defects in the late 1950s and early 1960s, was
the ﬁrst IMID to be investigated with regard to its immune-
modulating properties. The latter include antigen-
independent stimulation of T cells and activation of NK
cells [19]. It was later shown that second-generation IMIDs,
such as lenalidomide and pomalidomide, are even more
potent stimulators of T cellemediated immunity [20].
Activation of T cells requires signaling through the
T cellereceptor, for example provided by antigen-presenting
cells (APC), in combinationwith costimulating signals. IMIDs
stimulate only T cells that have been previously activated
by APC, such as dendritic cells. This activation abrogates
costimulation by APCs [21,22] and leads to a production
of Th1-type cytokines (interleukin-2, interferon-g) and
a down-regulation of Th2-type cytokines (interleukin-4 and
interleukin-10) [19]. T cell proliferation and cytokine
production is signiﬁcantly more ampliﬁed after stimulation
with lenalidomide and pomalidomide compared with
thalidomide; however, the clinical relevance of this ﬁnding
remains to be determined. Molecular mechanismsmediating
the IMID-induced proliferation and activation of T cells may
involve transcriptional activity of activated protein-1 [23],
increased tyrosine phosphorylation of CD28 on T cells
[21,22], and activation of the PI3K-signaling pathway in
activated T cells [21,22]. In vitro studies have shown that
despite the increase of interleukin-2, generation of regula-
tory T cells is inhibited. However, in vivo data suggest an
increase of FoxP3þ regulatory T cells after treatment with
lenalidomide; however, this was interpreted as a counter-
regulatory effect [24-26], as an increase of HLA-DRþ acti-
vated T cells preceded the increase of regulatory T cells [25].
IMIDs also stimulate the innate immune system,
including gd-T cells, NK cells, and NKT cells [20,21,27].
Lenalidomide increases dendritic celleinduced NKT cell
expansion and secretion of interferon-gamma [28]. Thalid-
omide, lenalidomide, and pomalidomide increase NK cell
proliferation in the presence of interleukin-2 [21], but only
lenalidomide and pomalidomide enhance antibody-
dependent cellular cytotoxicity, and natural cytotoxicity of
NK cells [28,29]. The presence of cyclosporine A may abro-
gate IMID-induced NK cell cytotoxicity, suggesting inter-
leukin-2-dependency of NK cell activation and proliferation
[27]. Furthermore, in the presence of IMIDs, activated NK
cells produce cytokines, such as monocyte chemotactic
protein and granulocyte-macrophage colony stimulating
factor, in response to antibody-coated target cells, which
might attract tumor-speciﬁc T cells and dendritic cells [30].
Lenalidomide was tested in a dose-ﬁnding study after
allo-SCT in multiple myeloma patients [31]. Lenalidomide
was given between day 100 and day 180, and the maximal
tolerable dose was 5 mg. Major toxicity was occurrence of
acute GvHD, which was observed in 38% of the patients.
Immune monitoring showed an early increase of g-interfer-
onesecreting CD4þ and C8þ T cells, which may explain the
onset of GvHD. In addition, an increase of NK cellemediatedtoxicity was seen, and the complete response rate increased
from 24% to 42%. A correlation between response and NK cell
and T cell activation was also noted. A similar incidence of
GvHD has been observed by the HOVON group [32], which
started lenalidomide at a dose of 10 mg 1 to 6 months after
nonmyeloablative allo-SCT for multiple myeloma. They
observed an increase of HLA-DRþ T cells, as well as of
regulatory T cells, but without correlation to clinical
outcome. In patients without complete remission after allo-
SCT, the remission status improved in 37% of the patients
after lenalidomide treatment, mainly by conversion from
partial response to very good partial response or complete
response.
Lenalidomide as salvage therapy in relapsed myeloma
patients after allo-SCT induced an overall response rate of
66% including 8% CR with only mild grade I to II GvHD in 12%
of the patients. In vivo measurement by ﬂow cytometry
showed signiﬁcant increase of activated NK (NKp44) as well
as T cells (CD3þHLA-DRþ) [25].
Although all studies reported high remission rates of
lenalidomide given after allo-SCT in myeloma patients,
which could be even higher than after autologous stem cell
transplantation [33], the effect of lenalidomide on GvHD
remains controversial. Lenalidomide in combination with
DLI was investigated in 12 myeloma patients who relapsed
after allo-SCT. DLI was administered after 2 cycles of lenali-
domide in an escalating mode, and no GvHD was seen [34].
In another study, lenalidomide was investigated as
post-transplantation therapy in MDS or AML with
del(5q)-abnormality. Lenalidomide (10 mg/day) was started
at a median of 2.5 months after allo-SCT without dexa-
methasone. The study was stopped prematurely because
6 out of 10 patients developed acute GvHD grade III or IV
[35]. In another trial, 16myeloma patients who relapsed after
allo-SCT received lenalidomide (25 mg/daily), either alone or
in combination with dexamethasone, resulting in an overall
response rate of 88%, and GvHD was seen only in patients
who received lenalidomidewithout dexamethasone (5 of 13)
[26]. These trials suggested that lenalidomide can cause
acute GvHD if given early after transplantation, and the risk
of GvHD is lower if the drug is given later or in combination
with dexamethasone.
Thalidomide given with a median dose of 200 mg as
salvage treatment for relapse after allo-SCT was investigated
in 33 patients by the Société Française de Greffe et de Moelle
et Thérapie Cellulaire. An objective response was seen in 29%
of the patients, but 5 patients (15%) developed acute GvHD
[36]. Low-dose thalidomide (100 mg), followed by DLI for
progressive disease or residual disease after allo-SCT, was
investigated in 18 patients with multiple myeloma post-
allograft [37]. Only 2 patients developed mild GvHD, and the
overall response was 67%, including 22% complete remis-
sions. In summary, IMIDs have immune-stimulatory prop-
erties, which can be used effectively after allo-SCT, but
because of the T cellestimulating effect, the risk of inducing
GvHD should be considered. (Table 1)
HYPOMETHYLATING AGENTS
Methylation plays a central role in epigenetic regulation
of gene expression [38]. Cancer cells use hypermethylation
to switch off a vast number of genes that are responsible
for growth inhibition, differentiation, and apoptosis [39].
Further epigenetic modiﬁcations are used extensively in
CD4 T cells to regulate linage commitment. DNA-methyl-
transferase-inhibitors azacytidine (AZA) or decitabine are
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Table 1
Immune-Modulating Properties of Novel Drugs
Drug Properties
IMIDs
Thalidomide
Lenalidomide
Pomalidomide
In vitro:
CD4 and CD8 and T cell
costimulation [19,21,22]
T regulatory cell suppression [20]
Th1-cytokine production [ [23]
DC-induced NKT cell expansion [ [27]
NK cell activation [21,25]
NK cell ADCC [ [27,29]
Gamma/delta T cells/NKT cells [ [20,21,27]
In vivo (human):
Increase in activated
T cells (CD3þ/HLADRþ) [25,33]
Increase in T regulatory
cells (delayed) [24e26,33]
Increase in NKp44 cells [25]
Hypomethylating
agents
5-Azacytidine In vitro:
Expression of canceretestis antigens
[[ on malignant cells [42,45,46]
T regulatory [[ [47]
Th1 YY [47]
In vivo:
T regulatory [[ [53]
CD8þ T cell response to
tumor-speciﬁc antigens [[ [53]
Decitabine NK cells: KIR expression [[ [47]
DC indicates dendritic cells; NK, natural killer; IMID, immune-modulating
drugs; KIR, killer immunoglobulin-like receptors.
N. Kröger et al. / Biol Blood Marrow Transplant 20 (2014) 168e172170clinically active in MDS and AML, and given their favorable
toxicity proﬁle, they represent a treatment modality that can
be used also after allo-SCT [40]. 5-AZA incorporated in both
RNA and DNA, unlike decitabine, which is only incorporated
in DNA [41]. The mechanism by which AZA exerts an anti-
tumor effect in MDS and AML remains not completely
understood. Several immunological mechanisms induced by
hypomethylating agents might contribute to their activity in
MDS and AML. In addition to its effect on gene modiﬁcation
for cell growth and differentiation, 5-AZA treatment leads to
upregulation of tumor-associated antigens, such as cancer-
etestis antigens, thereby potentially augmenting immune
recognition of malignancies [42-44]. In vitro studies with
cultured T cells demonstrated a decrease of CD8þ T cells
accompanied by an increase in CD4þ T cells after 5-AZA
treatment. In addition, numbers of interferon-gþ T-helper-
1-cells (Th1), as well as CD4þ and CD8þ memory T cells,
were strongly suppressed. Proportions of CD4þFoxP3þTcells
(regulatory T cells) showing a characteristic expression of
inhibiting cytokines: IL-10 and TGF-b increased in a dose-
dependent manner and, interestingly, 5-AZAetreated CD8þ
T cells showed a signiﬁcantly reduced capacity to kill AML
cells, independently from modulation by CD4þ T regulatory
cells [45]. Therefore, despite the ability to increase tumor-
speciﬁc antigens on tumor cells, the effect of hypo-
methylating agents on immune system is more suppressive.
In addition to the effect on T cellemediated immunity,
hypomethylating agents also inﬂuence innate immunity. KIR
expression and variability are regulated bymethylation in NK
cells. KIR hypomethylation is associated with KIR expression
and diversity [46]. Treatment of NK cells with the hypo-
methylating agent decitabine induces KIR expression on NK
cells, and thereby enhances KIR variability [47].
N. Kröger et al. / Biol Blood Marrow Transplant 20 (2014) 168e172 171Hypomethylating agents have been used after allo-SCT
[48]. The combination of hypomethylating agents and DLI
might be favorable, taking the enhanced expression of HLA
molecules as well as canceretestis antigens into account,
which might make leukemic cells more vulnerable to donor
T cell attack [44,49]. Decitabine has been used in relapsed
leukemia patients as single-agent salvage therapy with
second stem cell transplantation [50]. Graft failure has been
observed when decitabine was given too close after stem cell
transplantation, and the authors suggest an interference of
hypomethylating agent or its metabolite with stem cell
homing. 5-AZA was mostly used as salvage therapy for
recurrent disease after stem cell transplantation or even
when ongoing relapse was detected by decrease of CD34þ
cell lineage chimerism. Using single-agent 5-AZA in those
patients with a decrease of CD34 lineage chimerism to less
than 80%, 50% of the patients achieved a complete chimerism
and 30%, a stable donor CD34þ cell chimerism [51]. 5-AZA as
maintenance therapy has been shown to be feasible without
obvious increase in GvHD after transplantation [52,53].
5-AZA in combinationwith DLI for relapsed leukemia orMDS
patients has shown to be feasible with low risk of GvHD and
moderate toxicity, which was mainly hematotoxicity.
Furthermore, considerable response rates, even in patients
with high-risk cytogenetics, have been observed (see Table 2)
[54,55]. In 27 patients after allo-SCT for AML, to whom 5-AZA
was given at a dose of 36 mg/kg of body weight starting
day þ42 post-transplantation, an increase of T regulatory
cells was noted, and also in some patients, CD8þ T cell
responses to Wilms tumor antigen or melanoma-associated
antigen-1 was seen [56]. Hypomethylating agents are
currently used in clinical trials after allo-SCT.
In summary, using post-transplantation drug therapy is of
clinical interest to prevent relapse. Because of the tumor-
speciﬁc activities, hypomethylating agents have been used
primarily in myeloid malignancies, whereas immune-
modulating drugs have been more frequently used in
plasma cell disorders. Immune-modulatory properties of
IMIDs can be used mainly to stimulate, via T and NK cell
activation, GvL effect with the risk of GvHD, whereas hypo-
methylating agents can be used to avoid severe GvHD
without obvious increase of risk of relapse. Therefore,
depending on the primary aim for intervention, both drugs
can be used in combination with other cellular therapies
such as DLI. Prospective studies are warranted to reduce the
risk of relapse after allo-SCT.
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